STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access

STAT PlusPharmalot Supreme Court to hear case about ‘skinny labeling’ and generic access The session will be closely watched for its implications for the availability of generics Manage alerts for this article Email this article Share this article By Ed SilvermanApril 28, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. The Supreme Court on Wednesday will hear oral arguments about a simmering controversy over a wonky, but important topic called skinny labels, and the session will be closely watched for its implications for the availability of generic medicines. Skinny labeling refers to moves by generic companies that seek regulatory approval to market a medicine for a specific use, but not other patented uses for which a brand-name drug is prescribed. For instance, a generic drug could be marketed to treat one type of heart problem but not another. In doing so, the generic company seeks to avoid lawsuits claiming patent infringement.Advertisement This tactic has been a key tool for generic companies ever since the Hatch-Waxman Act was signed into law more than four decades ago. The law established the mechanisms by which generic drugs can more readily enter the marketplace. And skinny labeling, which amounts to a carve-out tactic, is one way that Congress attempted to foster more competition and benefit consumers. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Pharmaceuticals, Policy, STAT+, Supreme Court Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot April 28, 2026 STAT Plus: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more Pharmalot April 27, 2026 STAT Plus: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more Advertisement Pharmalot April 24, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot April 24, 2026 STAT Plus: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more Pharmalot April 23, 2026 STAT Plus: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards Subscriber Picks